📊 KZR Key Takeaways
Is Kezar Life Sciences, Inc. (KZR) a Good Investment?
Kezar Life Sciences exhibits exceptional financial stability with $66.2M in cash, zero debt, and a 9+ year cash runway, but remains pre-revenue with negative operating cash flow of -$7.4M. While improving net losses year-over-year suggest operational efficiency gains, the company lacks commercial traction and depends entirely on clinical/regulatory milestones not visible in financial data. Rating reflects strong balance sheet fundamentals offset by existential pre-revenue operational risk.
Kezar is a pre-revenue biotech with sustained operating losses and negative free cash flow, offset by a sizable cash balance and no debt. At the current burn (~$52M OCF) versus ~$72M cash, liquidity covers roughly 12–18 months before likely external financing is needed. Despite YoY loss improvement, fundamentals show no near-term path to profitability or revenue.
Kezar Life Sciences, Inc. Key Strengths (KZR)
- Exceptional cash position ($66.2M) representing 97% of total assets with zero long-term debt, providing 8-9 year runway at current burn rates
- No leverage or refinancing risk with current ratio of 24.46x and debt-to-equity of 0.00x
- Improving loss trajectory with 33% YoY improvement in net income indicating better operational efficiency
- Strong liquidity with 11.5x current ratio and ~$72M cash
- Debt-free balance sheet; minimal fixed obligations
- YoY improvement in net loss and negligible capex
KZR Stock Risks: Kezar Life Sciences, Inc. Investment Risks
- Pre-commercial stage with zero revenue generation; company entirely dependent on cash reserves without revenue traction
- Persistent negative operating cash flow of -$7.4M per period with no clear profitability pathway visible in financials
- Clinical-stage pharmaceutical development carries high regulatory failure risk and likely requires future capital raises causing shareholder dilution
- No revenue and persistent large operating losses
- Cash runway likely under two years, implying financing/dilution risk
- Negative ROE/ROA and interest coverage reflect weak profitability trajectory
Key Metrics to Watch
- Operating cash burn rate and changes to quarterly cash flow burn trajectory
- Absolute cash position and calculated runway extension as key survival metric
- Clinical trial advancement, regulatory filings, and potential revenue inception timeline
- Operating cash flow (burn rate)
- Cash & equivalents (runway)
Kezar Life Sciences, Inc. (KZR) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 24.46x current ratio provides a solid financial cushion.
KZR Profit Margin, ROE & Profitability Analysis
KZR vs Healthcare Sector: How Kezar Life Sciences, Inc. Compares
How Kezar Life Sciences, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Kezar Life Sciences, Inc. Stock Overvalued? KZR Valuation Analysis 2026
Based on fundamental analysis, Kezar Life Sciences, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Kezar Life Sciences, Inc. Balance Sheet: KZR Debt, Cash & Liquidity
KZR Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Kezar Life Sciences, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-14.04 indicates the company is currently unprofitable.
KZR Revenue Growth, EPS Growth & YoY Performance
KZR Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | N/A | -$20.3M | $-2.78 |
| Q3 2023 | N/A | -$16.0M | $-0.25 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Kezar Life Sciences, Inc. Dividends, Buybacks & Capital Allocation
KZR SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Kezar Life Sciences, Inc. (CIK: 0001645666)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| May 11, 2026 | 4 | xslF345X06/form4-05112026_040521.xml | View → |
| May 11, 2026 | 4 | xslF345X06/form4-05112026_040519.xml | View → |
| May 11, 2026 | 4 | xslF345X06/form4-05112026_040517.xml | View → |
| May 11, 2026 | 4 | xslF345X06/form4-05112026_040515.xml | View → |
| May 11, 2026 | 4 | xslF345X06/form4-05112026_040513.xml | View → |
❓ Frequently Asked Questions about KZR
What is the AI rating for KZR?
Kezar Life Sciences, Inc. (KZR) has a Combined AI Grade of C from Claude (B) and ChatGPT (C) with 55% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are KZR's key strengths?
Claude: Exceptional cash position ($66.2M) representing 97% of total assets with zero long-term debt, providing 8-9 year runway at current burn rates. No leverage or refinancing risk with current ratio of 24.46x and debt-to-equity of 0.00x. ChatGPT: Strong liquidity with 11.5x current ratio and ~$72M cash. Debt-free balance sheet; minimal fixed obligations.
What are the risks of investing in KZR?
Claude: Pre-commercial stage with zero revenue generation; company entirely dependent on cash reserves without revenue traction. Persistent negative operating cash flow of -$7.4M per period with no clear profitability pathway visible in financials. ChatGPT: No revenue and persistent large operating losses. Cash runway likely under two years, implying financing/dilution risk.
What is KZR's revenue and growth?
Kezar Life Sciences, Inc. reported revenue of $0.0.
Does KZR pay dividends?
Kezar Life Sciences, Inc. does not currently pay dividends.
Where can I find KZR SEC filings?
Official SEC filings for Kezar Life Sciences, Inc. (CIK: 0001645666) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is KZR's EPS?
Kezar Life Sciences, Inc. has a diluted EPS of $-0.78.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is KZR's fundamental grade?
Based on our AI fundamental analysis in June 2026, Kezar Life Sciences, Inc. has a C grade with 55% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is KZR stock overvalued or undervalued?
Valuation metrics for KZR: ROE of -8.8% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is KZR's AI grade for 2026?
Our dual AI analysis gives Kezar Life Sciences, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is KZR's free cash flow?
Kezar Life Sciences, Inc.'s operating cash flow is $-7.4M, with capital expenditures of $0.0.
How does KZR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -8.8% (avg: 15%), current ratio 24.46 (avg: 2).